Business
Devyser Diagnostics AB publishes quarterly report for the period April to June 2025
Devyser Diagnostics AB publishes quarterly report for the period April to June
About this update from Devyser Diagnostics Ab
[{"type":"text","content":"“A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost base going forward. If we continue to work on operational efficiency, we are confident that we will meet our communicated financial targets in 2026.”Fredrik Dahl, acting CEO, DevyserThe quarter from April to June 2025Net sales amounted to SEK 67.4 million (53.2), corresponding to a 26.6 percent increase. Adjusted for exchange rate fluctuations, net sales increased by 34.1 percent.Gross profit totaled SEK 56.8 million (41.4), corresponding to a gross margin of 84.2 percent (77.7).Operating profit (EBIT) amounted to SEK 5.5 million (-22.7).Profit after tax totaled SEK 1.3 million (-22.9).Earnings per share before and after dilution amounted to SEK 0.08 (-1.41).Cash flow from operating activities stood at SEK 2.3 million (-15.5).The period from January to June 2025Net sales amounted to SEK 122.2 million (104.0), corresponding to a 17.5 percent increase. Adjusted for exchange rate fluctuations, net sales increased by 20.7 percent.Gross profit totaled SEK 102.4 million (83.3), corresponding to a gross margin of 83.8 percent (80.1).Operating profit (EBIT) amounted to SEK -9.3 million (-36.7).Profit after tax totaled SEK -19.3 million (-35.1).Earnings per share before and after dilution amounted to SEK -1.16 (-2.15).Cash flow from operating activities stood at SEK -3.4 million (-33.9).Important events during the quarterJan Wahlström appointed as new CEO of DevyserIn April, Devyser’s Board of Directors announced the appointment of Jan Wahlström as the new CEO, effective August 2025. Jan Wahlström has extensive experience in the management and development of companies in the Health Care and Life Sciences field.Devyser won a large, SEK 61.8 million tender in ItalyIn April, Devyser signed a significant contract in Udine, Italy. The contract, which includes both NGS and FA products, will run for 36 months, and has been expanded by 10 percent compared with the previous, expired contract.Devyser launched Devyser HLA LossIn June, Devyser staged the global launch of Devyser HLA Loss, an NGS assay designed to offer the accurate, rapid and simple detection of HLA loss as part of post-transplant monitoring.Devyser launched Devyser Genomic Blood Typi...